Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: Lancet Oncol. 2020 Sep;21(9):e431–e443. doi: 10.1016/S1470-2045(20)30323-5

Table 1.

Relevant PRRT-related studies – molecular-based profiling, prognosis and prediction

Category Radiotherapy Parameters Type of Response Type of study Patient number Primary Site Refs
Prognostic 177 Lu-PRRT Various clinical parameters including SSR uptake PFS P, two-arm 221 Midgut 1
Prognostic None FDG-glucose uptake (imaging) PFS/OS NHx 100 All NET sites 51
Prognostic 177 Lu-PRRT Various including CgA, Ki-67 etc PFS/OS R 74 GEP-NET 55
Predictive 177 Lu-PRRT/ 90 Y-PRRT, mixed, and chemotherapy PPQ, transcriptomics, grade, CgA, SSR etc PFS P, single arm* 54 All NET sites 61
Predictive 177 Lu-PRRT/ 90 Y-PRRT, mixed, and chemotherapy PPQ, transcriptomics, grade, CgA, SSR etc PFS P, single arm* 158 All NET sites 62
Interventional 177 Lu-PRRT/ 90 Y-PRRT, mixed, and chemotherapy NETest, CgA PFS P, single arm 122 All NET sites 60
Toxicity 177 Lu-PRRT/ 90 Y-PRRT, mixed, and chemotherapy Various clinical and pathobiological parameters PFS/OS R 807 All NET sites 5

NHx = natural history (follow-up); (P), prospective study; (R), Retrospective study.

*

comparisons were made with separate study cohorts of SSA treatment and long-term follow-up